Illumina Inc. ($ILMN) Stock Forecast: Down 5.1% Today

What is Illumina Inc.?

A genomics company, Illumina, Inc. (NASDAQ: ILMN), specializes in DNA sequencing and genetic analysis technologies, catering to research, clinical, and applied markets.

Why is Illumina Inc. going down?

ILMN stock is down 5.1% on Jan 9, 2026 17:05

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Illumina, Inc. (NASDAQ: ILMN) has released Illumina Connected Multiomics, a new cloud-based research software platform designed to analyze and visualize complex multiomic and multimodal biological data. This platform aims to simplify multiomic analysis for researchers, integrating data across various 'omics' fields and enabling faster discovery in precision medicine. The software offers user-friendly tools, AI-driven analytics, and interactive visualizations, making advanced bioinformatics accessible to a wider range of scientists.

https://www.prnewswire.com/news-releases/illumina-launches-powerful-software-for-connected-intuitive-and-scalable-multiomic-analysis-302653576.html

DNA Test Kits Market Booming with Rapid Growth Through 2033 |Devyser, Illumina, Inc., Living DNA Ltd

The DNA Test Kits Market is projected to grow from USD 2.17 billion in 2025 to USD 6.36 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.6%. This growth is driven by rising industry demand, expanding applications, and technological advancements, with significant opportunities identified in various segments and regions. The report provides a comprehensive analysis of market dynamics, competitive landscape, and strategic insights for stakeholders.

https://www.openpr.com/news/4337544/dna-test-kits-market-booming-with-rapid-growth-through-2033

Why Illumina (ILMN) Is Up 6.5% After Advancing Grail Divestiture Plan And What's Next

Illumina's stock rose 6.5% after it advanced plans to divest its Grail cancer-diagnostics unit. This move aims to reduce regulatory pressure and allow Illumina to focus on its core DNA sequencing business, potentially reshaping investor perceptions of the company's future growth and earnings sustainability. The divestiture, along with ongoing share repurchases, is seen as key to clarifying Illumina's investment narrative, although risks concerning market demand remain.

https://uk.finance.yahoo.com/news/why-illumina-ilmn-6-5-042447132.html

Illumina’s Crossroads: Genomics Pioneer Tests Investor Patience As Wall Street Reassesses The Story

Illumina's stock has seen a slight dip amidst market caution, as the company works to resolve regulatory issues and refocus on its core sequencing growth. Investors are weighing whether the genomics pioneer is a turnaround success in the making or a cautionary tale, with sentiments shifting from earlier optimism. The market awaits clear signals regarding the divestiture of Grail, disciplined capital allocation, and re-accelerating sequencing demand to determine its future trajectory.

https://www.ad-hoc-news.de/boerse/ueberblick/illumina-s-crossroads-genomics-pioneer-tests-investor-patience-as-wall/68458500

Illumina (NASDAQ:ILMN) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen downgraded Illumina (NASDAQ:ILMN) from a "buy" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with an average price target of $118.31. Despite the downgrade, Illumina surpassed Q3 earnings estimates with EPS of $1.34 against expectations of $1.16 and revenue of $1.08 billion, also providing a strong FY2025 guidance. The company, trading within a 52-week range of $68.70–$153.06, holds a market capitalization of $20.53 billion, with institutional investors owning approximately 89.4% of the stock.

https://www.marketbeat.com/instant-alerts/illumina-nasdaqilmn-lowered-to-hold-rating-by-wall-street-zen-2026-01-03/

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.0% Today

Monero ($XMR) Crypto Forecast: Down 11.6% Today

Illumina Inc. Price History

16.09.2025 - ILMN Stock was up 5.2%

• The reasons behind the bullish movement in ILMN stock are:
• Favorable comparisons with another stock, potentially positioning ILMN as the more valuable choice.
• Investors seeking promising opportunities in the market may have been attracted by this comparison, resulting in heightened buying activity for ILMN shares.
• Positive perceptions of ILMN's technology and competitive position compared to its rival could have spurred increased demand for the stock.

15.08.2025 - ILMN Stock was up 5.2%

• The bullish movement in ILMN stock today can be attributed to the positive market sentiment surrounding the launch of the Illumina Protein Prep Assay.
• The rollout of this new product is expected to enhance Illumina's capabilities in multiomics research, which could lead to significant advancements in understanding various diseases.
• Investors are likely optimistic about the potential revenue growth and market expansion opportunities that the Illumina Protein Prep Assay could bring to the company, driving the stock's upward trajectory.

06.00.2026 - ILMN Stock was up 5.3%

• In spite of regulatory challenges and cautious sentiment from investors, Illumina demonstrated significant bullish momentum today.
• While receiving "hold" ratings from Wall Street Zen and Zacks Research, the company surpassed Q3 earnings projections and offered optimistic FY2025 guidance, resonating well with investors.
• The positive market response can be linked to hopeful investor sentiment regarding Illumina's anticipated recovery, supported by its strategic capital allocation and increasing demand for sequencing.
• Illumina's efforts to adapt to the AI era and consolidate its place in the genomics sector have instilled a sense of cautious optimism among investors and insiders about the company's future trajectory.

05.10.2025 - ILMN Stock was up 5.3%

• Following the company's surpassing of its third-quarter guidance and the narrowing of its full-year revenue decline forecast, Illumina's stock rose by over 23%, indicating optimistic growth prospects.
• Investor sentiment towards Illumina turned positive, with notable investors showing confidence in the company's future performance.
• The third-quarter earnings report exceeded expectations, reporting adjusted earnings of $1.34 per share, surpassing consensus estimates and contributing to the stock's significant increase.
• Illumina's ability to outperform expectations in both earnings and revenue for the quarter ended September 2025 showcases robust operational performance and potential for further growth in the genomics sector.

08.09.2025 - ILMN Stock was down 5.5%

• The bearish movement in ILMN today could be attributed to profit-taking by investors after a period of strong performance.
• The upcoming earnings report, despite expectations of a beat, might have led to some uncertainty among investors, causing a sell-off.
• The partnership with pharma companies for CDx development is a positive long-term move, but short-term investors might be reacting cautiously to the news, contributing to the bearish trend.
• Overall, the bearish movement in ILMN today seems to be a short-term market correction rather than a reflection of the company's fundamentals.

06.07.2025 - ILMN Stock was down 5.4%

• The bearish movement in ILMN stock today can be attributed to the settlement with the Department of Justice (DOJ) and Veterans to end a whistleblower lawsuit, leading to a significant financial payout.
• Despite reporting better-than-expected earnings for the second quarter and surpassing revenue estimates, the negative impact of the settlement on the company's finances likely overshadowed the positive financial results.
• Investors may be concerned about the implications of the settlement on Illumina's reputation and future legal challenges, leading to a sell-off of the stock.
• The market reaction reflects the delicate balance between financial performance and legal risks in the biotechnology sector, highlighting the importance of maintaining regulatory compliance and ethical standards to sustain investor confidence.

31.09.2025 - ILMN Stock was up 14.2%

• Exceeded earnings and revenue expectations for the third quarter.
• Positive surprise indicates strong demand for its products and services.
• Investors are optimistic about its future outlook.
• Market's bullish movement on ILMN today could be attributed to strong financial performance and growth opportunities in the genomics industry.

31.09.2025 - ILMN Stock was up 23.9%

• Illumina's stock soared today following better-than-expected third-quarter earnings.
• The company reported adjusted earnings of $1.34 per share, exceeding the consensus of $1.17, which contributed to the bullish movement.
• Positive earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025, further fueled investor confidence in Illumina's growth prospects.
• Overall, the strong financial performance and optimistic outlook from Illumina's earnings likely drove the bullish movement in the stock today.

31.09.2025 - ILMN Stock was up 25.0%

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

09.11.2025 - ILMN Stock was up 3.2%

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

09.00.2026 - ILMN Stock was down 5.1%

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.

01.09.2025 - ILMN Stock was up 6.5%

• Illumina's bullish movement today could be attributed to positive comparisons highlighting its value and growth potential in the precision oncology and biomedical sectors.
• Positive assessments of Illumina's growth momentum and value compared to other companies in the industry may have sparked investor interest and contributed to the stock's upward trajectory.
• Investors may view Illumina as a strong contender in the precision medicine space, driving demand for the stock and fueling its bullish movement.